The DNA methylome of benign and malignant parathyroid tumors.

Department of Surgery, Yale University , New Haven, CT; Yale Endocrine Neoplasia Laboratory, 333 Cedar Street, New Haven, CT 06520, USA.
Genes Chromosomes and Cancer (Impact Factor: 3.84). 06/2011; 50(9):735-45. DOI: 10.1002/gcc.20895
Source: PubMed

ABSTRACT The role of DNA methylation of CpG islands in parathyroid tumorigenesis has not been analyzed in an unbiased, systematic fashion. DNA was isolated from normal and pathologic parathyroid tissues, bisulphite modified and analyzed using the Infinium HumanMethylation27 BeadChip. Distinct hierarchical clustering of genes with altered DNA methylation profiles in normal and pathologic parathyroid tissue was evident. Comparing normal parathyroid tissue with parathyroid adenomas, 367 genes were significantly altered, while 175 genes significantly differed when comparing parathyroid carcinomas and normal parathyroid tissues. A comparison between parathyroid adenomas and parathyroid carcinomas identified 263 genes with significantly distinct methylation levels. Results were confirmed for certain genes in a validation cohort of 40 parathyroid adenomas by methylation-specific PCR. Genes of known or putative importance in the development of parathyroid tumors showed significant and frequent hypermethylation. DNA hypermethylation of CDKN2B, CDKN2A, WT1, SFRP1, SFRP2, and SFRP4 was associated with reduced gene expression in both benign and malignant parathyroid tumors. Treatment with 5-aza-2'-deoxycytidine of primary cell cultures restores expression of hypermethylated genes in benign and malignant parathyroid tumors. In conclusion, the unbiased, genome-wide study of the parathyroid tumor DNA methylome identified a number of genes with altered DNA methylation patterns of putative importance to benign and malignant parathyroid tumorigenesis.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aberrant epigenetics is a hallmark of cancer, and endocrine-related tumors are no exception. Recent research is identifying an ever-growing number of epigenetic alterations in both genomic DNA methylation and histone posttranslational modification in tumors of the endocrine system. Novel microarray and ultra deep sequencing technologies have allowed the identification of genome wide epigenetic patterns in some tumor types such as adrenocortical carcinoma, parathyroid and breast. However, in other cancer types, such as the multiple endocrine neoplasia syndromes and thyroid cancer, tumor information is limited to candidate genes alone. Future research should fill this gap and deepen our understanding of the functional role of these alterations in cancer, as well as defining their possible clinical uses.
    Endocrine Related Cancer 06/2014; · 4.91 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Inactivating mutations of the CDC73/HRPT2 tumor suppressor gene have been reported in parathyroid carcinomas, in association with the loss of nuclear expression of the encoding protein, parafibromin. The aim of the present study was to further investigate the role of the CDC73 gene in parathyroid carcinoma and evaluate whether the gene carrier status and/or the loss of parafibromin staining might have an impact in the outcome of the disease. We performed genetic and immunohistochemical studies in parathyroid tumor samples from 35 patients with sporadic parathyroid carcinoma. Nonsense or frameshift CDC73 mutations were detected in 13 samples suitable for DNA sequencing. Six of these mutations were germline. Loss of parafibromin expression was found in 17 samples. The presence of the CDC73 mutation as well as the loss of parafibromin predicted a high likelihood of subsequent recurrence and/or metastasis (92.3%, P=0.049 and 94.1%, P= 0.0083, respectively), but only the latter was associated with a decreased overall 5- and 10-year survival rates (59%, P=0.107, and 23%, P=0.0026, respectively). The presence of both CDC73 mutation and loss of parafibromin staining compared with their absence predicted a lower overall survival at 10- (18% vs 84%, P=0.016) but not at 5-year follow-up. In conclusion, loss of parafibromin staining better than CDC73 mutation predicts the clinical outcome and mortality rate. The added value of CDC73 mutational analysis is the possibility to identify germline mutations, which will prompt the screening other family members.
    Endocrine connections. 10/2013;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Multiple endocrine neoplasia type 1 (MEN1) is a familial syndrome characterized by the parathyroid, pancreas and pituitary tumors. Parathyroid tumors are the most common clinical manifestations, occurring in more than 90% of MEN1 patients. Heterozygous germline mutations of the MENIN gene underlie the tumorigenesis in MEN1 and epigenetic alterations along with germline mutations may contribute to tumorigenesis. Here, we investigated the associations between genotype and phenotype in Korean MEN1 patients.
    Endocrinology and metabolism (Seoul, Korea). 09/2014; 29(3):270-9.

Full-text (2 Sources)

Available from
Jun 10, 2014